七叶一枝花甾体皂苷种类及含量差异研究进展＊

重楼是我国传统的名贵中药，七叶一枝花为历版《中国药典》收载的重楼药材两个基原植物之一，具有清热解毒、消肿止痛、活血化瘀等功效，其主要活性成分为甾体皂苷类物质。由于重楼市场需求量剧增和七叶一枝花成药时间较长，导致大量依靠人工种植。然而，人工种植过程中产地、采收年限和采收月份都会影响七叶一枝花的甾体皂苷含量。本文系统地总结了七叶一枝花中主要活性成分甾体皂苷的种类，以及不同产地、不同生长年限及不同采收月份的七叶一枝花根茎中甾体皂苷含量差异的研究现状，以期为进一步研究七叶一枝花品质差异、野生资源驯化及规范化种植提供参考。     

Proteomics analysis of lysine crotonylation and 2-hydroxyisobutyrylation reveals significant features of systemic lupus erythematosus

Introduction/objectives

To seek significant features of systemic lupus erythematosus (SLE) by utilizing bioinformatics analysis.

Method

Liquid chromatography-tandem mass spectrometry (LC–MS/MS) was used to quantify lysine crotonylation (Kcr) and lysine 2-hydroxyisobutyrylation (Khib) in peripheral blood mononuclear cells (PBMCs) of systemic lupus erythematosus (SLE) patients and normal controls.

Results

Seventy-six differentially modified proteins (DMPs) dually modified by Kcr and Khib were identified between SLE patients and healthy people. GO enrichment analysis prompted significant enrichment of seventy-six DMPs in MHC class II protein complex binding and leukocyte migration. KEGG pathways were enriched in antigen processing and presentation pathway and leukocyte transendothelial migration pathway. Six DMPs (CLTC, HSPA1B, HSPA8, HSP90AB1, HSPD1, and PDIA3) were identified in antigen processing and presentation pathway, of which HSPA8 was the core protein. Significant changes of Kcr and Khib in HSPA8 may increase ATP hydrolysis and promote antigen binding to MHC II molecule. In leukocyte transendothelial migration pathway, 7 DMPs (ACTN1, ACTN4, EZR, MSN, RAC1, RHOA, and VCL) were identified. MSN was the protein with the most modification sites in this pathway. In amino terminal ferm region of MSN, Kcr and Khib expression change may lead to the adhesion between leukocytes and endothelial cells, which was an important step of leukocyte migration.

Conclusion

Kcr and Khib may promote the antigen presentation and jointly regulate the tissue damage mediated by leukocyte migration in SLE patients, which may play key roles in the pathogenesis of SLE probably.

我国护士对多点执业认知与实践体验的Meta整合

目的 系统评价我国护士参与多点执业体验的质性研究，为推行护士多点执业提供切实可行的参考方案。方法 计算机检索中英文数据库中关于护士参与多点执业的质性研究，检索时间截至2022年6月。采用JBI质性研究质量评价标准对所纳入的文献进行文献质量评价，使用汇集性整合方法对结果进行整合。结果 共纳入13篇研究，提炼50个结果，归纳形成12个类别，最终整合成4个结果，包括护士对多点执业的态度；护士进行多点执业的促成因素；护士进行多点执业的阻碍因素；护士对多点执业的期望。结论 目前护士多点执业有诸多阻碍因素,医院管理者应重视护士多点执业真实体验，结合相关部门完善政策制定，完善多点执业管理制度，规范多点执业服务流程。     

IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4

Investigational New Drugs - Background Chemotherapy resistance is a main reason for treatment failure in extranodal NK/T-cell lymphoma (ENKTL). Interleukin-10 (IL-10) is closely related to...     

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric,gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.     

首批依诺肝素钠国家对照品1,6-脱水衍生物含量赋值的协作研究

目的： 建立首批1,6-脱水衍生物系统适用性对照品，完善国家标准。方法：以欧洲药典依诺肝素钠对照品(EP Enoxaparin Sodium，Batch5)为系统适用性对照品，采用依诺肝素钠新国家标准草案 “1,6-脱水衍生物”检查法，对依诺肝素钠国家对照品(批号：140810-201801)进行1,6-脱水衍生物含量测定，由全国14个药品检验机构及依诺肝素生产企业实验室协作标定。结果：对依诺肝素钠系统适用性国家对照品(批号：140810-201801)1,6-脱水衍生物含量标定结果为20.3%，并对实验室内误差进行考察，14个实验室中有1个实验室(Lab1)标准差(SD)为1.8%，5个实验室(Lab2、Lab4、Lab10、 Lab11和Lab13)的SD为0.5%~0.7%，其余8个实验室的SD值均小于0.5%。对实验室间误差进行考察，有效数据的SD值为0.6%，相对标准偏差(RSD)为3.2%。结论：经国家药品标准物质委员会审定后批准， 依诺肝素系统适用性国家对照品(批号：140810-201801)增加1,6-脱水衍生物含量赋值，可以用于依诺肝素钠1,6-脱水衍生物检查系统适用性考察使用。